The Hearing Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Hearing Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hearing Disorders. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Hearing Disorders - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hearing Disorders and features dormant and discontinued products.

GlobalData tracks 87 drugs in development for Hearing Disorders by 59 companies/universities/institutes. The top development phase for Hearing Disorders is preclinical with 48 drugs in that stage. The Hearing Disorders pipeline has 81 drugs in development by companies and six by universities/ institutes. Some of the companies in the Hearing Disorders pipeline products market are: Regeneron Pharmaceuticals, Ting Therapeutics and Acousia Therapeutics.

The key targets in the Hearing Disorders pipeline products market include Potassium Voltage Gated Channel Subfamily KQT Member 4 (Potassium Channel Subunit Alpha KvLQT4 or Voltage Gated Potassium Channel Subunit Kv7.4 or KCNQ4), Gap Junction Beta 2 Protein (Connexin 26 or GJB2), and Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

The key mechanisms of action in the Hearing Disorders pipeline product include Potassium Voltage Gated Channel Subfamily KQT Member 4 (Potassium Channel Subunit Alpha KvLQT4 or Voltage Gated Potassium Channel Subunit Kv7.4 or KCNQ4) Activator with five drugs in Phase I. The Hearing Disorders pipeline products include 11 routes of administration with the top ROA being Oral and ten key molecule types in the Hearing Disorders pipeline products market including Small Molecule, and Gene Therapy.

Hearing Disorders overview

Hearing loss is an extremely common medical condition, ranging from neonates to the elderly, progressing in incidence and severity with age; about one-third of older adults have hearing loss. Diagnosis and management require an interprofessional team that includes the general practitioner, otolaryngologist, speech therapist, audiologist, and social worker. To correctly address hearing loss, understanding the nature of hearing loss and the equipment that is needed to improve auditory reception is crucial. In terms of children’s hearing loss, pediatricians need to be integrated into their care to ensure normal hearing and language development of the child. Hearing loss is a common problem caused by loud noise, aging, disease, and genetic variations. The three basic categories of hearing loss are sensorineural hearing loss, conductive hearing loss, and mixed hearing loss. Conductive involves the outer or middle ear, sensorineural involves the inner ear, and mixed involves both. Symptoms of hearing loss may include muffling of speech and other sounds, trouble hearing letters of the alphabet that aren’t vowels, and often asking others to speak more slowly, clearly, and loudly.

For a complete picture of Hearing Disorders’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.